High-risk GD2-Positive Ewing Sarcoma
1 clinical trials · Condition
◉ Watch High-risk GD2-Positive Ewing Sarcoma
| Record | Firm | Date |
|---|---|---|
| International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma (NCT06839703) | Prof. Dr. Dirk Reinhardt | 2025-03-01 |
Track High-risk GD2-Positive Ewing Sarcoma automatically
Every clearance here is in the API, with alerts when new ones post.